|
US5658920A
(en)
|
1991-01-16 |
1997-08-19 |
Daiichi Pharmaceutical Co., Ltd. |
Substituted 1H,12H-benz-[DE]pyrano[3',4':6,7] indolizino[1,2-B]quinoline-10,13(9H,15H)-dione compound
|
|
US6504029B1
(en)
|
1995-04-10 |
2003-01-07 |
Daiichi Pharmaceutical Co., Ltd. |
Condensed-hexacyclic compounds and a process therefor
|
|
IL123147A
(en)
|
1995-08-02 |
2004-02-19 |
Univ Newcastle Ventures Ltd |
Benzamide imidazole - 4 carboxamide and their use
|
|
DE69707860T2
(de)
|
1996-04-26 |
2002-04-11 |
Daiichi Pharmaceutical Co., Ltd. |
Verfahren zur herstellung von tetrahydroindolizinen
|
|
TW527183B
(en)
|
1996-06-06 |
2003-04-11 |
Daiichi Seiyaku Co |
Drug complex
|
|
TW409058B
(en)
|
1996-06-06 |
2000-10-21 |
Daiichi Seiyaku Co |
Method for preparation of a drug complex
|
|
IN189180B
(https=)
|
1997-07-09 |
2003-01-04 |
Chong Kun Dang Corp |
|
|
MY132496A
(en)
|
1998-05-11 |
2007-10-31 |
Vertex Pharma |
Inhibitors of p38
|
|
HK1040052B
(zh)
|
1998-05-22 |
2006-09-15 |
第一制药株式会社 |
药物复合物
|
|
ID29943A
(id)
|
1998-10-30 |
2001-10-25 |
Daiichi Seiyaku Co |
Senyawa dds dan metode pengukurannya
|
|
DE59911249D1
(de)
|
1998-11-03 |
2005-01-13 |
Abbott Gmbh & Co Kg |
Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung
|
|
OA11749A
(en)
|
1999-01-11 |
2005-07-19 |
Agouron Pharma |
Tricyclic inhibitors of poly(adp-ribose)polymerases.
|
|
DE19920936A1
(de)
|
1999-05-07 |
2000-11-09 |
Basf Ag |
Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
|
|
ECSP003637A
(es)
|
1999-08-31 |
2002-03-25 |
Agouron Pharma |
Inhibidores triciclicos de poli (adp-ribosa) polimerasas
|
|
US6699876B2
(en)
|
1999-11-18 |
2004-03-02 |
Les Laboratoires Servier |
Camptothecin analogue compounds
|
|
CA2396513A1
(en)
|
1999-12-13 |
2001-06-14 |
Yanzhi Zhang |
Pseudomycin phosphate prodrugs
|
|
HUP0300590A2
(hu)
|
2000-03-15 |
2003-07-28 |
Bristol-Myers Squibb Pharma Company |
Peptidázzal hasítható, célzott antineoplasztikus szerek és terápiás alkalmazásuk
|
|
MXPA03000387A
(es)
|
2000-07-13 |
2003-09-22 |
Daiichi Seiyaku Co |
Derivados de 4-fenil-piridina como antagonistas del receptor de neuroquinina-1.
|
|
US7151102B2
(en)
|
2000-10-30 |
2006-12-19 |
Kudos Pharmaceuticals Limited |
Phthalazinone derivatives
|
|
US6441163B1
(en)
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
|
EP1487493B1
(en)
|
2002-03-01 |
2010-01-20 |
The Administrators of The Tulane Educational Fund |
Conjugates of cytotoxic agents and biologically active peptides
|
|
HRP20040853A2
(en)
|
2002-03-20 |
2004-12-31 |
Bristol Myers Squibb Co |
Phosphate prodrugs of fluorooxindoles
|
|
DE60335359D1
(de)
|
2002-04-30 |
2011-01-27 |
Kudos Pharm Ltd |
Phthalazinonderivate
|
|
US7449464B2
(en)
|
2003-03-12 |
2008-11-11 |
Kudos Pharmaceuticals Limited |
Phthalazinone derivatives
|
|
MXPA05010563A
(es)
|
2003-03-31 |
2005-11-23 |
Pfizer |
Sales de los inhibidores triciclicos de las poli(adp-ribosa) polimerasas.
|
|
KR101424624B1
(ko)
|
2003-05-14 |
2014-07-31 |
이뮤노젠 아이엔씨 |
약물 콘쥬게이트 조성물
|
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
|
US7276497B2
(en)
|
2003-05-20 |
2007-10-02 |
Immunogen Inc. |
Cytotoxic agents comprising new maytansinoids
|
|
PL3524611T3
(pl)
|
2003-05-20 |
2021-06-14 |
Immunogen, Inc. |
Udoskonalone czynniki cytotoksyczne zawierające nowe maitansynoidy
|
|
SI1660095T1
(sl)
|
2003-07-25 |
2010-05-31 |
Cancer Rec Tech Ltd |
Triciklični parp inhibitorji
|
|
GB0317466D0
(en)
|
2003-07-25 |
2003-08-27 |
Univ Sheffield |
Use
|
|
KR20060123403A
(ko)
|
2003-12-01 |
2006-12-01 |
쿠도스 파마슈티칼스 리미티드 |
암 치료를 위한 ｄｎａ 손상 수복 억제제
|
|
EP1718667B1
(en)
|
2004-02-23 |
2013-01-09 |
Genentech, Inc. |
Heterocyclic self-immolative linkers and conjugates
|
|
JP5149620B2
(ja)
|
2004-07-23 |
2013-02-20 |
エンドサイト，インコーポレイテッド |
２価リンカーおよびその結合体
|
|
EP1799685B1
(en)
|
2004-09-22 |
2012-03-28 |
Pfizer Inc. |
Polymorphic forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
|
|
EP1793830A2
(en)
|
2004-09-22 |
2007-06-13 |
Pfizer, Inc. |
Therapeutic combinations comprising poly(adp-ribose) polymerases inhibitor
|
|
DK1794163T3
(da)
|
2004-09-22 |
2010-04-12 |
Pfizer |
Fremgangsmåde til fremstilling af poly(ADP-ribose)polymeraseinhibitorer
|
|
PL1819359T3
(pl)
|
2004-12-09 |
2015-08-31 |
Janssen Biotech Inc |
Immunokoniugaty skierowane przeciw integrynie, metody ich wytwarzania oraz ich zastosowanie
|
|
WO2006078816A2
(en)
|
2005-01-18 |
2006-07-27 |
The Board Of Governors For Higher Education |
Selective delivery of molecules into cells or marking of cells in diseased tissue regions using environmentally senstive transmembrane peptide
|
|
US7301019B2
(en)
|
2005-01-21 |
2007-11-27 |
Immunogen, Inc. |
Method for the preparation of maytansinoid esters
|
|
CA2597407C
(en)
|
2005-02-11 |
2013-09-10 |
Immunogen, Inc. |
Process for preparing stable drug conjugates
|
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
|
EA200702239A1
(ru)
|
2005-04-15 |
2008-10-30 |
Иммьюноджен, Инк. |
Уничтожение гетерогенной или смешанной клеточной популяции в опухолях
|
|
EP3539572A1
(en)
|
2005-08-24 |
2019-09-18 |
ImmunoGen, Inc. |
Process for preparing maytansinoid antibody conjugates
|
|
EP1957477B1
(en)
|
2005-09-29 |
2011-12-07 |
Abbott Laboratories |
1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors
|
|
WO2007056550A2
(en)
|
2005-11-08 |
2007-05-18 |
Immunogen, Inc. |
Processes for preparation of maytansinol
|
|
ME02121B
(me)
|
2006-01-17 |
2014-06-30 |
Abbvie Ireland Unlimited Co |
Kombinovana terapija sa parp inhibitorima
|
|
CN101479295A
(zh)
|
2006-05-04 |
2009-07-08 |
健泰科生物技术公司 |
涉及zpa多肽的方法和组合物
|
|
UY30639A1
(es)
|
2006-10-17 |
2008-05-31 |
Kudos Pharm Ltd |
Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
|
|
AR064777A1
(es)
|
2007-01-10 |
2009-04-22 |
Inst Di Reserche D Biolog Mole |
Indazoles sustituidos con amida como inhibidores de poli (adp- ribosa) polimerasa (parp)
|
|
WO2008114114A2
(en)
|
2007-03-16 |
2008-09-25 |
Pfizer Products Inc. |
Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition
|
|
BRPI0812970A2
(pt)
|
2007-06-25 |
2019-09-24 |
Endocyte Inc |
conjugados contendo espaçadores hidrofílicos
|
|
US8067613B2
(en)
|
2007-07-16 |
2011-11-29 |
Abbott Laboratories |
Benzimidazole poly(ADP ribose)polymerase inhibitors
|
|
EP4464384A3
(en)
|
2007-08-17 |
2025-01-08 |
Purdue Research Foundation |
Psma binding ligand-linker conjugates and methods for using
|
|
EP2276506A4
(en)
|
2008-04-30 |
2014-05-07 |
Immunogen Inc |
EFFICIENT CONJUGATES AND HYDROPHILIC BINDER
|
|
ES2617619T3
(es)
|
2008-06-05 |
2017-06-19 |
Janssen Pharmaceutica, N.V. |
Combinaciones de fármacos que comprenden un inhibidor de DGAT y un agonista de PPAR
|
|
BRPI1010620B8
(pt)
|
2009-06-03 |
2021-05-25 |
Immunogen Inc |
métodos de conjugação
|
|
US9353140B2
(en)
|
2009-11-25 |
2016-05-31 |
Academia Sinica |
BQC-G, a tumor-selective anti-cancer prodrug
|
|
EP2534153B2
(en)
|
2010-02-12 |
2024-05-22 |
Pfizer Inc. |
Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
|
|
CA2790577A1
(en)
|
2010-02-25 |
2011-09-01 |
Purdue Research Foundation |
Psma binding ligand-linker conjugates and methods for using
|
|
PT2609923T
(pt)
|
2010-03-31 |
2017-08-30 |
Gilead Pharmasset Llc |
Processo para a cristalização de 2-(((s)- (perfluorofenoxi)(fenoxi)fosforil)amino)propanoato de (s)-isopropilo
|
|
EP2566335B1
(en)
|
2010-05-05 |
2016-06-29 |
Prolynx Llc |
Controlled release of active compounds from macromolecular conjugates
|
|
EP2603231B1
(en)
*
|
2010-07-13 |
2021-12-29 |
Rhode Island Board Of Governors For Higher Education |
Compositions comprising a pH-sensitive membrane insertion polipeptide.
|
|
EP2603201B1
(en)
|
2010-08-13 |
2020-03-11 |
Rhode Island Board of Governors for Higher Education |
Liposome compositions and methods of use thereof
|
|
CN103269712B
(zh)
|
2010-11-03 |
2016-09-21 |
伊缪诺金公司 |
包含新型安丝菌素衍生物的细胞毒性剂
|
|
WO2012135517A2
(en)
|
2011-03-29 |
2012-10-04 |
Immunogen, Inc. |
Preparation of maytansinoid antibody conjugates by a one-step process
|
|
RS58367B1
(sr)
|
2011-03-29 |
2019-03-29 |
Immunogen Inc |
Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
|
|
JP6104257B2
(ja)
|
2011-10-14 |
2017-03-29 |
メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ |
ピロロベンゾジアゼピンおよびそのコンジュゲート
|
|
DK2907824T3
(en)
|
2012-10-11 |
2018-07-23 |
Daiichi Sankyo Co Ltd |
ANTIBODY-drug conjugate
|
|
EP2910573B1
(en)
|
2012-10-19 |
2020-02-19 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate produced by binding through linker having hydrophilic structure
|
|
EP2911701A4
(en)
|
2012-10-23 |
2016-06-08 |
Univ Johns Hopkins |
Novel self-assembling drug amphiphiles and methods for synthesis and application
|
|
WO2014093343A2
(en)
|
2012-12-10 |
2014-06-19 |
Massachusetts Institute Of Technology |
Multistage nanoparticle drug delivery system for the treatment of solid tumors
|
|
JP6262768B2
(ja)
|
2013-01-03 |
2018-01-17 |
セルトリオン， インク． |
抗体−リンカー−薬物結合体、その製造方法およびそれを含む抗癌剤組成物
|
|
JP6494533B2
(ja)
|
2013-02-28 |
2019-04-03 |
イミュノジェン・インコーポレーテッド |
細胞結合剤及び細胞毒性剤としてのマイタンシノイドを含む複合体
|
|
JP6701077B2
(ja)
|
2013-12-19 |
2020-05-27 |
シアトル ジェネティックス， インコーポレイテッド |
標的化薬物結合体と使用するためのメチレンカルバメートリンカー
|
|
EP3094752A4
(en)
|
2014-01-16 |
2017-08-16 |
Clovis Oncology, Inc. |
Use of parp inhibitors to treat breast or ovarian cancer patients showing a loss of heterozygosity
|
|
EP3099717B1
(en)
|
2014-01-31 |
2019-03-27 |
Novartis AG |
Antibody molecules to tim-3 and uses thereof
|
|
JP2017114763A
(ja)
|
2014-03-26 |
2017-06-29 |
第一三共株式会社 |
抗ｃｄ９８抗体−薬物コンジュゲート
|
|
JP6612738B2
(ja)
|
2014-04-10 |
2019-11-27 |
第一三共株式会社 |
抗ｈｅｒ２抗体−薬物コンジュゲート
|
|
KR102399277B1
(ko)
|
2014-04-10 |
2022-05-18 |
다이이찌 산쿄 가부시키가이샤 |
항her3 항체-약물 콘주게이트
|
|
WO2016004043A1
(en)
|
2014-06-30 |
2016-01-07 |
Blend Therapeutics, Inc. |
Targeted conjugates and particles and formulations thereof
|
|
KR102803917B1
(ko)
|
2014-08-22 |
2025-05-07 |
파르마＆ 슈바이츠 게엠베하 |
루카파립의 고 용량 강도 정제
|
|
CN106470697B
(zh)
|
2014-09-16 |
2019-10-25 |
兴盟生物医药(苏州)有限公司 |
抗egfr抗体以及其用途
|
|
CN117138060A
(zh)
|
2014-10-07 |
2023-12-01 |
免疫医疗公司 |
抗体-药物缀合物的新辅助剂用途
|
|
EP3220959A1
(en)
|
2014-11-19 |
2017-09-27 |
ImmunoGen, Inc. |
Process for preparing cell-binding agent-cytotoxic agent conjugates
|
|
JO3705B1
(ar)
|
2014-11-26 |
2021-01-31 |
Bayer Pharma AG |
إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
|
|
KR102407261B1
(ko)
|
2015-02-27 |
2022-07-06 |
서울대학교산학협력단 |
나노 항암제형 및 그 제조 방법
|
|
EP3362100B1
(en)
|
2015-10-16 |
2022-06-22 |
Genentech, Inc. |
Hindered disulfide drug conjugates
|
|
JP7057278B2
(ja)
|
2015-10-28 |
2022-04-19 |
ターベダ セラピューティクス インコーポレイテッド |
Ｓｓｔｒ標的化コンジュゲート及び粒子並びにその製剤
|
|
ES2784523T3
(es)
|
2015-11-24 |
2020-09-28 |
Theravance Biopharma R&D Ip Llc |
Profármacos de un compuesto inhibidor de JAK para el tratamiento de enfermedades inflamatorias gastrointestinales
|
|
KR102498258B1
(ko)
|
2016-01-20 |
2023-02-10 |
삼성디스플레이 주식회사 |
표시 장치
|
|
US20170267727A1
(en)
|
2016-03-04 |
2017-09-21 |
Lehigh University |
Conjugates of pH Low Insertion Peptide and Monomethyl Auristatins in the Treatment of Solid Tumors
|
|
EP3426301A4
(en)
|
2016-03-08 |
2019-11-06 |
Los Gatos Pharmaceuticals, Inc. |
VERBUNDNANOPARTICLES AND USES THEREOF
|
|
US20200078468A1
(en)
|
2016-04-13 |
2020-03-12 |
Tarveda Therapeutics, Inc. |
Neurotensin receptor binding conjugates and formulations thereof
|
|
GB201608885D0
(en)
|
2016-05-20 |
2016-07-06 |
Univ Birmingham |
Treatment
|
|
US20190133980A1
(en)
|
2016-06-02 |
2019-05-09 |
Yale University |
Compositions and methods for targeting and treating homologous recombination-deficient tumors
|
|
WO2018023098A1
(en)
|
2016-07-29 |
2018-02-01 |
Memorial Sloan Kettering Cancer Center |
Radiolabeled ligands for targeted pet/spect imaging and methods of their use
|
|
PH12019500306B1
(en)
|
2016-08-16 |
2024-02-21 |
Aist |
Malignant tumor target peptide
|
|
US11779662B2
(en)
*
|
2016-09-22 |
2023-10-10 |
University Of Rhode Island Board Of Trustees |
Fluorescent compound comprising a fluorophore conjugated to a pH-triggered polypeptide
|
|
ES2921236T3
(es)
|
2016-11-25 |
2022-08-22 |
Mabwell Shanghai Bioscience Co Ltd |
Enlazador de amida maleica disustituida para la conjugación de anticuerpo y fármaco y método de preparación y uso del mismo
|
|
EP3554638B1
(en)
|
2016-12-19 |
2022-02-02 |
Morehouse School of Medicine |
Compositions and methods for treating diseases by inhibiting exosome release
|
|
WO2018227132A1
(en)
|
2017-06-09 |
2018-12-13 |
Rhode Island Council On Postsecondary Education |
Linked and other ph-triggered compounds
|
|
BR112020003466B1
(pt)
|
2017-08-31 |
2023-12-12 |
Daiichi Sankyo Company, Limited |
Métodos de produção de composto, e, composto
|
|
KR20200121800A
(ko)
|
2018-01-05 |
2020-10-26 |
싸이브렉사 1, 인크. |
산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법
|
|
MX2020007306A
(es)
|
2018-01-12 |
2020-09-25 |
Prolynx Llc |
Tratamiento sinergico de cancer.
|
|
HUE067382T2
(hu)
|
2018-05-18 |
2024-10-28 |
Daiichi Sankyo Co Ltd |
Anti-MUC1-exatecan antitest-hatóanyag konjugátum
|
|
TWI851577B
(zh)
|
2018-06-07 |
2024-08-11 |
美商思進公司 |
喜樹鹼結合物
|
|
CN109232719B
(zh)
|
2018-09-21 |
2021-06-29 |
中国科学院理化技术研究所 |
一种pH响应的抗菌肽及其制备方法和应用
|
|
WO2020160009A1
(en)
*
|
2019-01-28 |
2020-08-06 |
Rhode Island Council On Postsecondary Education |
Phlip® targeted delivery of potent cytotoxic compounds
|
|
HUE060364T2
(hu)
|
2019-03-29 |
2023-02-28 |
Medimmune Ltd |
Vegyületek és konjugátumaik
|
|
CN114341162B
(zh)
|
2019-07-10 |
2025-10-17 |
赛博克萨2公司 |
作为治疗剂的细胞毒素的肽缀合物
|
|
TW202116356A
(zh)
|
2019-07-10 |
2021-05-01 |
美商斯布雷克薩三號公司 |
作為治療劑之微管靶向藥劑之肽結合物
|
|
US20240093250A1
(en)
|
2021-01-08 |
2024-03-21 |
Cybrexa 2, Inc. |
Process for preparing a conjugate linking moiety
|
|
CN117897175A
(zh)
|
2021-04-29 |
2024-04-16 |
美商斯布雷克萨二号公司 |
拓扑异构酶i抑制剂的肽缀合物的给药方案
|
|
JP2024542212A
(ja)
|
2021-11-17 |
2024-11-13 |
サイブレクサ ４，インコーポレイテッド |
治療薬としてのペプチドチューブリン阻害剤のペプチドコンジュゲート
|